Dr. Henry Ji to Participate in a Fireside Chat at the B. Riley Securities Oncology Investor Conference on Jan 20, 2021
19 January 2021 - 6:05PM
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento"), announced
today that Dr. Henry Ji, Chairman and CEO, will participate in the
following upcoming conference:
- Fireside chat during the B. Riley
Securities Oncology Investor Conference being held virtually. The
fireside chat is scheduled to take place on Wednesday, January 20,
2021 at 2:30 PM ET.
A live webcast of this presentation will be available for
registered participants at:
https://b-riley-oncology-investor-conference.events.issuerdirect.com/signup
The fireside chat will be available for 90+ days following the
event at:
https://www.webcaster4.com/Webcast/Page/2433/39569
About Sorrento Therapeutics, Inc.
Sorrento is a clinical stage, antibody-centric,
biopharmaceutical company developing new therapies to treat
cancers. Sorrento's multimodal, multipronged approach to fighting
cancer is made possible by its extensive immuno-oncology platforms,
including key assets such as fully human antibodies (“G-MAB™
library”), clinical stage immuno-cellular therapies (“CAR-T”,
“DAR-T”), antibody-drug conjugates (“ADC”), and clinical stage
oncolytic virus (“Seprehvir®”). Sorrento is also developing
potential antiviral therapies and vaccines against coronaviruses,
including COVI-GUARD™, COVI-AMG™, COVI-SHIELD™, Gene-MAb™,
COVI-MSC™ and COVI-DROPS™; and diagnostic test solutions, including
COVI-TRACK™, COVI-STIX™ and COVI-TRACE™.
Sorrento's commitment to life-enhancing therapies for patients
is also demonstrated by our effort to advance a first-in-class
(TRPV1 agonist) non-opioid pain management small molecule,
resiniferatoxin (“RTX”), and SP-102 (10 mg, dexamethasone sodium
phosphate viscous gel) (SEMDEXA™), a novel, viscous gel formulation
of a widely used corticosteroid for epidural injections to treat
lumbosacral radicular pain, or sciatica, and to commercialize
ZTlido® (lidocaine topical system) 1.8% for the treatment of
post-herpetic neuralgia. RTX has completed a phase IB trial for
intractable pain associated with cancer and a phase 1B trial in
osteoarthritis patients. SEMDEXA is in a pivotal Phase 3 trial for
the treatment of lumbosacral radicular pain, or sciatica. ZTlido®
was approved by the FDA on February 28, 2018.
For more information visit www.sorrentotherapeutics.com
Forward-Looking Statements
This press release and any statements made for and during any
presentation or meeting contain forward-looking statements related
to Sorrento Therapeutics, Inc. under the safe harbor provisions of
Section 21E of the Private Securities Litigation Reform Act of 1995
and subject to risks and uncertainties that could cause actual
results to differ materially from those projected. Forward-looking
statements include statements regarding the developments of and
prospects for Sorrento's and its subsidiaries’ and affiliates’
products, product candidates and technologies, including its plans
and goals with respect to its strategic outlook and clinical and
pre-clinical therapeutic and diagnostic programs and pipeline and
Sorrento's M&A and licensing strategy. Risks and uncertainties
that could cause our actual results to differ materially and
adversely from those expressed in our forward-looking statements,
include, but are not limited to: risks related to Sorrento's and
its subsidiaries', affiliates’ and partners’ technologies and
prospects and collaborations with partners; clinical development
risks, including risks in the progress, timing, cost, and results
of clinical trials and product development programs; risk of
difficulties or delays in obtaining regulatory approvals; risks
that clinical study results may not meet any or all endpoints of a
clinical study and that any data generated from such studies may
not support a regulatory submission or approval; risks that prior
test, study and trial results may not be replicated in future
studies and trials; risks related to seeking regulatory approvals
and conducting clinical trials; risks of manufacturing and
supplying drug product; risks related to leveraging the expertise
of its employees, subsidiaries, affiliates and partners to assist
the company in the execution of its therapeutic and diagnostic
product candidate strategies; risks related to the global impact of
COVID-19; and other risks that are described in Sorrento's most
recent periodic reports filed with the Securities and Exchange
Commission, including Sorrento’s Annual Report on Form 10-K for the
year ended December 31, 2019, and subsequent Quarterly Reports on
Form 10-Q filed with the Securities and Exchange Commission,
including the risk factors set forth in those filings. Investors
are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date of this release and we
undertake no obligation to update any forward-looking statement in
this press release except as required by law.
Media and Investor Relations
Contact: Alexis Nahama, DVM (SVP Corporate
Development)Telephone: 1.858.203.4120Email:
mediarelations@sorrentotherapeutics.com
Sorrento® and the Sorrento logo are registered trademarks of
Sorrento Therapeutics, Inc.G-MAB™, DAR-T™, COVI-GUARD™, COVI-AMG™,
COVI-SHIELD™, Gene-MAb™, COVI-DROPS™, COVI-MSC™, COVI-TRACK™,
COVI-TRACE™ and COVI-STIX™ are trademarks of Sorrento Therapeutics,
Inc.
SEMDEXA™ is a trademark of Semnur Pharmaceuticals, Inc.
ZTlido® is a registered trademark owned by Scilex
Pharmaceuticals Inc.
All other trademarks are the property of their respective
owners.
© 2021 Sorrento Therapeutics, Inc. All Rights Reserved.
Sorrento Therapeutics (NASDAQ:SRNE)
Historical Stock Chart
From Apr 2024 to May 2024
Sorrento Therapeutics (NASDAQ:SRNE)
Historical Stock Chart
From May 2023 to May 2024